Sector News

Novartis names GSK exec new Sandoz CEO, a familiar face with a digital spin to it

April 24, 2019
Life sciences

Novartis is transforming Sandoz to be an autonomous unit within the larger company, and it has tapped a former exec from the biz, and an ex-GSK digital lead, to take the reins, fitting neatly into CEO Vas Narasimhan’s digital ambition for the Big Pharma.

Richard Saynor, currently senior VP of classic & established products and commercial & digital platforms at GlaxoSmithKline, will become CEO of Sandoz by Aug. 1, Novartis said on Wednesday alongside its first-quarter results.

Saynor will fill a vacancy now covered ad interim since Richard Francis, its former CEO, left at the end of March. Top on his to-do list will be seeing through what Narasimhan called a multiyear transformation that focuses on turning Sandoz into a standalone unit within the large company, a task that will allow it “the right capabilities and the right freedom to operate in order to be successful,” the CEO said on a Wednesday briefing with reporters.

The new chief is no stranger to Sandoz—he once held commercial leadership roles at the generics unit and oversaw its expansion in Asia, Latin America and Turkey. But on top of his familiarity with the franchise, Narasimhan might have seen something else in Saynor—his experience in digital solutions.

In addition to running $10 billion worth of established products at GSK, Saynor also oversees the commercial digital platforms across all of the British drugmaker’s pharma portfolios. That means, Narasimhan will have a digital veteran on the Sandoz level to carry out his vision of turning Novartis into a medicines company powered by data science and advanced therapy platforms.

Toward the digital part of that goal, Novartis has brought on ex-Argos chief digital and marketing officer Bertrand Bodson as its first chief digital officer shortly before Narasimhan officially took over as CEO. Last March, the company signed up with Pear Therapeutics to work on software applications that aim to treat schizophrenia and multiple sclerosis.

For Sandoz specifically, it followed up with that Pear partnership and took on the responsibility of selling two prescription digital therapeutics: reSET and reSET-O, for patients with substance use disorder or with opioid use disorder, respectively.

Sandoz is still under generics pricing pressure in the U.S., which has continuously hurt its performance. In the first quarter, sales were off 2% on constant currencies, as U.S. pricing was again cited as the culprit behind the drop. The $2.33 billion it raked in came slightly below analysts’ consensus, according to Jefferies.

There have been speculations that Novartis is granting Sandoz autonomy only for the convenience of a future sale or spinoff. Narasimhan, on the company’s results call this morning, said “no real change” is happening to its plan for Sandoz and again stressed that the three-pronged overhaul could take several years to complete.

Right now, it is trying to improve the overall cost base of Sandoz and revamping its portfolio to focus on hard-to-make generics and biosimilars. Geographically, it is still on track to sell its U.S. dermatology and oral solids portfolio to India’s Aurobindo within this year, and is planning to exit some regions, including parts of Africa, where it’s not in a good position to compete, according to Narasimhan.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach